Glonghui, April 2 | Lepu Bio-B (2157.HK) rose intraday today, at one point rising by more than 13% to HK$3.61. According to the news, the company announced results on March 27, showing that revenue in 2023 increased from about RMB 16 million in the previous year to about RMB 225 million, an increase of about 1347.2%; the company's losses to its mother fell sharply by about 96.8%, from about RMB 689 million in the previous year to about RMB 122 million in the same year. According to reports, Lepu Bio-B achieved breakthrough revenue during the reporting period. The Group's BD revenue and subsequent technical service revenue was approximately RMB 124 million, and the commercial revenue of Puyouheng (putrizumab injection) was approximately RMB 101 million.
港股异动丨乐普生物大涨超13%，2023年收入大增1347.2%
Changes in Hong Kong stocks 丨 Lepu Biotech surged more than 13%, and revenue surged 1347.2% in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.